Elanco Animal Health (NYSE:ELAN) Updates FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.800-0.860 for the period, compared to the consensus earnings per share estimate of 0.900. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its FY25 guidance to $0.80-$0.86 EPS.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Leerink Partners assumed coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price on the stock. Stifel Nicolaus decreased their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday. Barclays upped their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. UBS Group started coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Morgan Stanley lowered their price target on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of “Hold” and a consensus price target of $16.00.

Elanco Animal Health Stock Down 5.1 %

Shares of NYSE ELAN traded down $0.56 during mid-day trading on Tuesday, reaching $10.55. The company had a trading volume of 1,252,305 shares, compared to its average volume of 4,574,833. The stock has a market capitalization of $5.21 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a twelve month low of $10.20 and a twelve month high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock’s 50 day moving average is $11.78 and its 200-day moving average is $13.09.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.08 earnings per share. As a group, equities analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.